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Abstract The aging lung is increasingly susceptible to infectious disease. Changes in pulmonary physiology and function
are common in older populations, and in those older than 60 years, pneumonia is the major cause of infectious death.
Understanding age-related changes in the innate and adaptive immune systems, and how they affect both pulmonary and
systemic responses to pulmonary challenge are critical to the development of novel therapeutic strategies for the treatment
of the elderly patient. In this observational study, we examined age-associated differences in inflammatory responses to
pulmonary challenge with cell wall components from Gram-positive bacteria. Thus, male Sprague–Dawley rats, aged
6 months or greater than 18 months (approximating humans of 20 and 55–65 years), were challenged, intratracheally, with
lipoteichoic acid and peptidoglycan. Cellular and cytokine evaluations were performed on both bronchoalveolar lavage
fluid (BAL) and plasma, 24 h post-challenge. The plasma concentration of free thyroxine, a marker of severity in non-
thyroidal illness, was also evaluated. The older animals had an increased chemotactic gradient in favor of the airspaces,
which was associated with a greater accumulation of neutrophils and protein. Furthermore, macrophage migration inhi-
bitory factor (MIF), an inflammatory mediator and putative biomarker in acute lung injury, was increased in both the
plasma and BAL of the older, but not young animals. Conversely, plasma free thyroxine, a natural inhibitor of MIF, was
decreased in the older animals. These findings identify age-associated inflammatory/metabolic changes following pul-
monary challenge that it may be possible to manipulate to improve outcome in the older, critically ill patient.
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Introduction
In normal individuals, the maximum functional ability of
the lungs occurs between the ages of 20–25 years, after
which there is a progressive decline in performance [1].
The changes are mainly associated with decreases in static
elastic recoil, compliance of the chest wall, and in the
strength of respiratory muscles. In later life, the suscepti-
bility to lung infection also increases, and pneumonia
occurs in around 25–44 cases per 1000 non-institutional-
ized elderly individuals [2], and in those older than
65 years old, pneumonia is the major cause of infectious
death [3]. Studies of critically ill patients have identified
advanced age and pulmonary staphylococcal infection as
leading causes of sepsis [4]. Acute lung injury (ALI) or the
adult respiratory distress syndrome (ARDS), as it is now
more formally known in humans [5], is a major compli-
cation of nosocomial pneumonia [6] and is associated with
acute inflammation leading to disruption of the lung
epithelial and endothelial barriers. The inflammation is
associated with greatly increased accumulation of neu-
trophils and other inflammatory cells induced by increased
chemotaxins within the alveolae [7–9]. The injury is also
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associated with increased accumulation of the proinflam-
matory mediator macrophage migration inhibitory factor
(MIF) within the airspaces [10]. MIF has been shown to be
released by the lungs, into the systemic circulation, where
it induces cardiocirculatory depression [11]. Because of its
importance in acute inflammation, several groups have
developed inhibitory antibodies [12–14] and synthetic
small molecule inhibitors of MIF [15–18], and shown that
they can prevent morbidity and mortality associated with
endotoxemia and sepsis [16, 18–20]. Interestingly, MIF has
the ability to override the anti-inflammatory activity of
glucocorticoids [21], which, although their use remains
controversial, have been used as therapeutic agents in the
treatment for ARDS [22–24]. Furthermore, recent studies
have shown that the thyroid hormone thyroxine, which is
often decreased in critically ill patients, even in the absence
of thyroidal illness [25], is a natural inhibitor of the
proinflammatory active site of MIF [26].
In this observational study, components of the cell wall of
Gram-positive bacteria, such as S. aureus, were used to incite
an acute lung inflammation. We then evaluated age-depen-
dent changes in the inflammatory response, in both the blood
and alveolar compartments, at 24 h following the insult.
Methods
Animals Studies
All animal experiments received prior approval by the
Institutional Animal Care and Use Committee of The
Feinstein Institute. Male Sprague–Dawley rats (4 or
12 months of age) were purchased from Charles River
(Kingston, NY). The latter were housed under standard
conditions and provided with standard rodent chow and
water, until experimentation at 18–20 months of age.
Experimental Protocol
Three groups were investigated. Young (\6 months saline;
\6 months LTA ? PGN) and old ([18 months
LTA ? PGN). Each rat (n = 6 per group) was weighed and
then anesthetized to a surgical plane using isoflurane. The
tracheawas then surgically exposed and cell wall components
from Gram-positive bacteria lipoteichoic acid (0.15 mg) and
peptidoglycan (0.5 mg), or saline alone in 100 ml sterile
0.9 % saline, was instilled intratracheally using a 29-gauge
needle. The woundwas then closed using 5.0 silk sutures, and
the animals were allowed to recover. Once ambulant, they
were returned to normal housing and allowed food and water
ad libitum. After 24 h, the animals were re-anesthetized with
isoflurane and exsanguinated via cardiac puncture, and the
blood was collected for analysis. Postmortem, the lungs were
lavaged with two aliquots (7 ml each) of sterile saline
(0.9 %w/v). The bronchoalveolar lavage fluid (BAL) from
each lavage was collected in separate tubes. The tubes were
centrifuged, and supernatant was stored in-80 C. Only the
supernatant from the first tube was used for measuring
chemokines, cytokines, and protein content, whereas BALF
from both tubes was used for cell counting [27].
Analysis of Bronchoalveolar Lavage Fluid
BAL cells were mixed with 0.5 ml of 0.2 % saline for 10 s
to lyse any residual erythrocytes. The cells were then
resuspended in 10 ml Hank’s buffered salt solution
(HBSS). Total cell number was determined with a hemo-
cytometer. Slides were prepared using a Shandon cyto-
centrifuge (Shandon Scientific, London, UK), and cells
were stained with Wright-Giemsa stains (HEMA 3 Stain
Set, Fisher Scientific, Pittsburgh, PA) for differential cell
counting. Counts were made on at least 200 cells per slide.
Protein concentrations in BAL were assessed by BCA
method (Pierce, Rockford, IL).
Commercially available enzyme-linked immunosorbent
assay (ELISA) kits were used to assay MIF and KC
(MyBioSource, San Diego, CA) and free thyroxine (Gen-
way Biotech, Inc., San Diego, CA) following the manu-
facturers’ instructions.
Statistical Analysis
Data are presented as mean ± standard deviation. One-
way ANOVA was used to evaluate the statistical signifi-
cance of the results. Difference with p value\ 0.05 was
considered significant.
Results
Body Weight Increased with Age
Sprague–Dawley rats can live up to 3.5 years, and males
reach an adult body weight of between 450 and 520 g
around 12 weeks old. In the current study, the body
weights of the rats were 473 ± 38 g in the\6-month group
and 641 ± 45 g in the[18-month group (Fig. 1). How-
ever, in the current study, animals were challenged with the
same amount of LTA and PGN, and it was not titered with
respect to body weight.
Polymorphonuclear Leukocyte (Neutrophil) Influx
into the Airspaces
Neutrophils accumulate at a site of inflammation by
responding to a chemotactic gradient. In rats, KC (CXCL1)
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and its cellular receptor CXCR2 have been shown to be a
major chemokine for the pulmonary recruitment of neu-
trophils [28]. Therefore, we measure the concentration of
this chemokine in both plasma and the airspaces, and
assessed its association with the accumulation of neu-
trophils within the alveolae. Following pulmonary chal-
lenge, there was a significant increase (p = 0.05) in the
percentage of neutrophils in the blood of the \6-month
group (69 ± 13 %) compared to controls (39 ± 10 %).
However, in the older group [18 months, there was no
significant increase in the percentage of blood neutrophils
(42 ± 14 %). Concurrently, in the BAL, the total number
of neutrophils significantly increased from control values
in both groups of rats treated with LTA–PGN (Fig. 2a).
The neutrophilic influx was associated with a significant
accumulation of KC within the airspaces of the older ani-
mals (43.8 ± 18.5 ng/ml) compared to controls
(16.5 ± 4.0) and\6-month group (21.6 ± 6.6). However,
this was not reflected in the plasma accumulation of KC
controls (4.2 ± 5.9 ng/ml); \6 months (3.7 ± 1.4);
[18 months (2.3 ± 1.5). Since neutrophil chemotaxis
depends on the movement of cells along a chemotactic
gradient, we assessed the ratio of the concentration of KC
in the BAL and plasma (Fig. 2b). While there was no
significant difference between the younger groups, in this
respect, the[18 months was significantly greater than the
other two groups. It should be noted that BAL is approx-
imately 100-fold more dilute than the epithelial lining fluid
that it samples [7]. Thus, there is a considerable chemo-
tactic gradient between the blood and alveolar spaces in the
LTA–PGN challenged animals. The influx of neutrophils
was associated with significantly increased accumulation
of protein (p\ 0.05) in the \6-month group
(427 ± 208 lg/ml) and [18-month-old group
(584 ± 297 lg/ml) within the alveolar space of challenged
animals compared to controls (108 ± 40 lg/ml), suggest-
ing that some injury to the airspaces had occurred in each
of the challenged groups.
Macrophage Migration Inhibitory Factor
Accumulation
While MIF is found within the airspaces of normal lungs,
there is a significant increase in accumulation in the alveolar
airspaces of patients with ARDS [10]. In addition, animal
studies suggest that there is enhanced MIF expression in the
alveolar endothelium and infiltrating macrophages in ARDS
[14, 29], and that the lungsmay act as an inflammatory organ
releasingMIF into the systemic circulation [30], where it can
induce cardiocirculatory depression [11]. Therefore, we
examined the concentration of MIF in blood and BAL fol-
lowing pulmonary challenge. At 24 h post-challenge, there
was only an increase inMIF of the plasma of the[18-month-
old group (Fig. 3a). However, a significant increase in
plasma MIF was only see in two (33 %) of the animals. A
more profound increase in MIF concentration was noted
within the airspaces of the older group (Fig. 3b).
Free Thyroxine Evaluation
A characteristic finding in patients with critical illness is an
alteration in circulating thyroid hormone levels including
thyroxine (T4). The changes in thyroid hormone concen-
trations are directly correlated to the severity of the disease
and are associated with poor survival [31]. Accordingly, we
measured plasma free T4 in the rats following pulmonary
challenge (Fig. 4). The median free T4 was significantly
Fig. 1 Body weights prior to pulmonary challenge. The weights of
the older animals were significantly greater than those of the younger
group (*p\ 0.05)
Fig. 2 Neutrophil
accumulation in the airspaces of
the lungs a was significantly
greater in the rats challenged
with LTA and PGN than in
controls. b The ratio of the KC
concentration in the BAL and
Plasma KC was significantly
higher in the[18-month group
than in either of the other two
groups (*p\ 0.05)
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lower in the older age group (1.02 ng/dl) than the controls
(1.55 ng/dl). However, there was no difference between the
young group (1.20 ng/dl) and controls.
Discussion
The ability of the body to mount a concerted response is an
evolutionary advantage. In the case of bacterial challenges,
our body is tested by a diverse, complex and dynamic
challenge, and must adapt its constitutive functions to repel
the threat. In many cases, the response to the challenge is
appropriate and homeostasis maintained. However, there
are other situations in which the body’s overall inflam-
matory response is seemingly inappropriate, lacking
effectiveness, and leads to detrimental effects and even
death.
Infection by the Gram-positive bacteria Staphylococcus
aureus or Streptococcus pneumonia is a common cause of
pneumonia, especially in elderly patients [32–34]. The
elderly are at increased risk of pneumonia due to age-re-
lated deterioration of lung function [35]. Studies of criti-
cally ill patients have identified advanced age and
pulmonary S. aureus infection as leading causes of sepsis
[4]. During the progression of infection and pneumonia,
ALI can develop. ALI is a major clinical condition which
affects nearly 200,000 individuals annually in the USA
[36] and a major complication of nosocomial pneumonia
[37]. The clinical manifestations include severe hypoxemia
with acute onset and bilateral infiltrates on chest radiog-
raphy [38]. Although effective ventilator and fluid man-
agement strategies have been developed, mortality remains
high at 25–35 % [39–41]. Age is a critical determinant of
the incidence and mortality of ALI [incidence: 16 per
100,000 person-years in young (15–19 years of age) and
306 per 100,000 person-years (75–84 years of age) mor-
tality: 24 % (15–19 years) to 60 % ([85 years)] [36].
Critically ill patients with ALI or its most severe form
ARDS, have an increased capillary permeability, which
results in significant fluid imbalance, oncotic pressure
changes, pulmonary edema, and alveolar collapse [42].
While comorbidities such as chronic obstructive pul-
monary disease (COPD) and cardiovascular disease are
major risk factors for pneumonia in the elderly, it is also
clear that there are changes in the inflammatory response
even in the healthy individual [43]. While studies show that
pro-inflammatory cytokines in blood and tissues are higher
than in their young counterparts [44, 45], this may not be
the complete, or indeed the fundamental, reason for the
increased mortality. Thus, it remains unclear whether there
are alterations in magnitude of the response or whether the
normally highly orchestrated sequence of events is dys-
regulated. The sequence of events that occur in the
inflammatory response is critical to the effectiveness of that
response.
Animal studies involving older animals are expensive
and often more difficult to perform due to the ‘‘fragility’’ of
the animal with greater morbidity and mortality associated
with this group. Also, as in the current study, the variability
of the responses in the older animals is greater than their
younger counterparts. Therefore, many of the studies
involving acute lung inflammation, ALI, and sepsis are
performed in young animals, and there is much less
information about the pathophysiology of acute inflam-
mation, which is specific to older patients [46]. However,
studies have shown important age-associated increase in
mortality, hypothermia, and induction of IL-6 following
Fig. 3 MIF concentration in
both the plasma (a) and the
airspaces (b) was significantly
greater in the older animals than
in controls (*p\ 0.05) or the
younger animals following an
identical pulmonary challenge
(#p\ 0.05)
Fig. 4 Plasma free thyroxine (fT4) was significantly decreased in the
older animals 24 h post-pulmonary challenge (*p\ 0.05)
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Gram-negative or [47] Gram-positive [48] challenge.
While the current study only examines one dose of bacte-
rial toxin and one time point of sampling, it highlights
some pertinent differences between the groups and changes
that occur following pulmonary challenge in a rat model of
acute inflammation, and the differing response to an
identical challenge in the older animal group. First, the
body weights of the older age group, prior to challenge,
were significantly greater than controls. Starr et al. [49]
have shown that white adipose tissue is a major source of
interleukin-6 (IL-6), a proinflammatory cytokine mediating
the severity of sepsis [50]. Furthermore, obesity is associ-
ated with an increased number of activated circulating
neutrophils [51]. Previous studies have shown that acti-
vated neutrophils have a longer life span than their quies-
cent counterparts [52]. Interestingly, 24 h post-challenge,
there was no change in the percentage of neutrophils in the
blood of the older group, but there were more neutrophils
in the airspaces. The increased accumulation was associ-
ated with a more profound chemotactic gradient, in favor
of the airspaces, in the older animals (Fig. 2). This suggests
that in the younger animals, the neutrophil recruitment had
terminated earlier than in the older group. Perhaps more
importantly, the inflammatory effects of the chemokine
may be more profound in the older group. This is because
KC and its human counterpart Interleukin-8 not only
induce neutrophil chemotaxis, but at higher concentrations
initiate neutrophil degranulation and the generation of
hydrogen peroxide and superoxide anion [28, 53]. Of note,
elevated levels of interleukin-8 are present in the airspaces
of patients with the adult respiratory distress syndrome and
are associated with increased mortality [7].
We also found increased accumulation of MIF in both
the plasma and airspaces of the older animals 24 h post-
challenge. MIF is a relatively small protein mediator pro-
duced by numerous cell types, including alveolar macro-
phages [30], neutrophils [31], pulmonary epithelial cells
[32], and pulmonary endothelial cells [32, 33]. During
severe infection, MIF accumulates both in the parenchymal
tissue and in the alveolar spaces. The intra-alveolar MIF
interacts with CD74 expressed on the surface of alveolar
macrophage cells, inducing p44/p42 MAPK activation and
chemokine release [35]. Furthermore, the MIF can be
released into the systemic circulation where it induces
cardiocirculatory depression [34, 36]. Notably, the increase
in MIF was concurrent with a significant decrease in free
T4 (Fig. 4). T4 has been shown to be a potent natural
inhibitor of MIF, and that plasma MIF and fT4 concen-
trations are inversely correlated in patients with severe
sepsis [26]. The study also showed that in thyroid-deficient
animals, the outcome from severe infection is worse than
euthyroid animals, and that inhibition of MIF with the
hormonally inactive D-isomer of T4 protects against
mortality. Furthermore, Ma et al. [54] have shown that
acute lung injury is associated with an upregulation of type
2 deiodinase (DIO2) which metabolizes T4 into tri-
iodothyronine (T3), a molecule involved in surfactant
homeostasis and lung compliance [55, 56]. Thus, there may
be many reasons for the low fT4 during acute lung injury.
However, reduced availability of T4 may have profound
downstream effects on lung function. This may be of par-
ticular importance to the older population, in whom an
existing mild or subclinical hypothyroidism is more com-
mon [57], may also worsen many risk factors [58], and be
directly related to the severity of acute illness [31].
Summary
Changes in pulmonary physiology, pathology, and function
are common in older populations, and lead to altered
responses and increased morbidity and mortality associated
with lung infections. However, in many respects, the rea-
sons for the altered susceptibility remain unclear. There
may be interactions between inflammatory and metabolic
pathways, such as with MIF and T4, or T3 and surfactant
homeostasis, that are not immediately obvious. While the
benefit of direct supplementation of thyroid hormones in
patients with critical illnesses such as ARDS or sepsis
remains unclear [59], perhaps addressing the possible
causes of the deficiency may prove more effective, as they
have in animal models [11, 26, 54, 60, 61]. What is clear is
that a better understanding of age-related changes in the
innate and adaptive immune systems within the pulmonary
compartment, and their impact on lung host defense, is of
critical importance for developing effective therapeutic
strategies for the treatment of the elderly patient.
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